The global glycogen synthase kinase 3 beta market is anticipated to grow at a significant CAGR 1.9% during the forecast period (2022-2028). Glycogen synthase kinase 3, or GSK-3 refers to a serine/threonine, proline-directed kinase that is associated with a diverse array of signaling pathways, which includes cellular adhesion and glycogen synthesis. The compounds derived from natural sources come mainly from plants or marine organisms, and include Indirubin, Hymenialdisine, Meridianins, Manzamines, Palinurin, and Tricantin. Another promising opportunity for the market growth includes the favorable outcome of the glycogen synthase kinase 3 beta in the treatment of bipolar disorder. As per the Institute for Health Metrics and Evaluation (IHME), Global Burden of Diseases, the prevalence of bipolar disorder across the world varies from 0.3 to 1.2% by country. In 2017, around 46 million people around the globe had bipolar disorder, with 52% and 48% being female and male, respectively. The typical age of onset is the late teens or the early 20s, and a history of depression is common in people diagnosed with bipolar.

The major factor primarily attributed to the market growth include the growing use of these inhibitors in in vivo models and in numerous clinical trials. Since 2011, substantial developments in glycogen synthase kinase 3 beta were witnessed in the form of products that include AZD1080 from AstraZeneca and LY2090314 from Eli-Lilly (both ATP competitive inhibitors). Unfortunately, their development was discontinued due to safety issues. Further, glycogen synthase kinase beta is further likely to be used in the treatment of musculoskeletal disorder, lung cancer, dyskinesia, and Menkes disease, among others. 

Some key players operating in the market include AstraZeneca plc, Eli Lilly and Co., and Santa Cruz Biotechnology, Inc., among others. 

Market Coverage

• The market number available for – 2021-2028

• Base year- 2021

• Forecast period- 2022-2028

• Segment Covered- 

o By Type

o By Indication

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  AstraZeneca plc, Eli Lilly and Co., and Santa Cruz Biotechnology, Inc., among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Glycogen Synthase Kinase 3 Beta Market Report by Segment

By Type

• AZD1080

• LY2090314

• AP-001

• AP-1

• DM-204

• Neu-120

• Others

By Indication

• Musculoskeletal Disorder 

• Lung Cancer 

• Dyskinesia

• Menkes Disease

• Inflammatory Disease

• Others

Global Glycogen Synthase Kinase 3 Beta Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa